We Elevate Great Companies Together
50 - 300 m €
We invest in profitable medium-sized companies with a turnover of between EUR 50 million and EUR 300 million.
18 %
The average annual EBITDA growth of our investments is 18 per cent.
1,6 bn €
Capiton AG currently manages a fund volume of approximately €1.6 billion.
80 +
The Capiton team has supported more than 80 companies. Over 70 investments have been completed.
Innovative ideas, market access, change expertise and fresh capital: that's all you need for the future of your medium-sized company. You have the ideas and the market access, Capiton brings everything else to the collaboration and paves the way to the future together with you. In partnership and with competence.
Capital for the future
Capiton
Overview
Focus on High-Tech Industrials & Healthcare & Life Sciences
We invest in companies in the High-Tech Industrials and Healthcare & Life Sciences sectors.
Rooted in the Mittelstand
As an owner-managed, mid-market investment company, we focus on companies with annual revenues of between EUR 50 million and EUR 300 million.
Top in the DACH region
With a clear focus on the German-speaking region, we are one of the most successful mid-cap PE investors in the DACH region.
Side by Side, as Partners
We combine years of market experience with entrepreneurial thinking. This makes us an equal partner for the Mittelstand.
Wundex is a service provider in the healthcare sector that, with Capiton’s support, has grown from a regional provider into the market leader in Germany. For the management and co-shareholders, one thing is clear: Capiton was the right partner to drive sustainable growth.
14. Nov 2025 Capiton strengthens leadership team with the appointment of Fritjof Franz as additional Managing Partner
30. Sep 2025 Capiton V realizes successful 100% Exit from Dec Group. Successor Fund capiton VI acquires cV shareholding together with Private Equity firm ICG to drive long-term growth
25. Aug 2025 capiton successfully sells its stake in KM Packaging to the ALPLA Group
22. Aug 2025 MiP Pharma sells Homburg/Saar production site and focuses on growth through the distribution of its own pharmaceutical products
Contact
News
Stay up to date
Sign up for our newsletter.